Skip to main content
SpringerLink
Log in

MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review

  • Review
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide and within the United States. Liver transplant or partial liver resection is the definitive treatment of choice for HCC; however, the majority of cases are detected in advanced stages due to its early-stage asymptomatic nature, often precluding surgical treatment. Locoregional therapy plays an essential role in HCC management, including curative intent, as a bridge to transplant, or in some cases palliative therapy. Radiologists play a critical role in assessing tumor response following treatment to guide further management that may potentially impact transplantation eligibility; therefore, it is important for radiologists to have an understanding of different locoregional therapies and the variations of imaging response to different therapies. In this review article, we outline the imaging response to ablative therapy (AT), transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), and stereotactic body radiation therapy (SBRT). We will also briefly discuss the basic concepts of these locoregional therapies. This review focuses on the imaging features following locoregional treatment for hepatocellular carcinoma following AT, TACE, SIRT, and SBRT.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  2. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone A-M, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785–800.

    Article  PubMed  Google Scholar 

  3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis [Internet]. https://doi.org/10.1056/NEJM199603143341104. 2009 [cited 2019 Dec 21]. Available from: https://doi.org/10.1056/NEJM199603143341104?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov

  4. Jadlowiec CC, Taner T. Liver transplantation: Current status and challenges. World J Gastroenterol. 2016 May 14;22(18):4438–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016 Oct 5;3:41–53.

    Article  Google Scholar 

  6. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2002 Oct;8(10):873–83.

    Google Scholar 

  7. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol Baltim Md. 2018;67(1):358–80.

    Article  Google Scholar 

  8. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul 1;69(1):182–236.

    Article  Google Scholar 

  9. Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jun 15;11(4):317–70.

    Article  PubMed  Google Scholar 

  10. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018 Mar 31;391(10127):1301–14.

    Article  Google Scholar 

  11. European Association For the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–43.

    Article  Google Scholar 

  12. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52–60.

    Article  CAS  PubMed  Google Scholar 

  13. Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, et al. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol N Y. 2018;43(10):2625–42.

    Article  Google Scholar 

  14. Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, et al. Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm. Abdom Radiol N Y. 2018 Jan;43(1):218–30.

    Article  Google Scholar 

  15. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update. Radiology. 2014 Jun 13;273(1):241–60.

    Article  PubMed  Google Scholar 

  16. Li J-K, Liu X-H, Cui H, Xie X-H. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol. 2020 Jan;12(1):15–22.

    Google Scholar 

  17. Xu X-L, Liu X-D, Liang M, Luo B-M. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology. 2018;287(2):461–72.

    Article  PubMed  Google Scholar 

  18. Nahon P, Vibert E, Nault J-C, Ganne‐Carrié N, Ziol M, Seror O. Optimizing curative management of hepatocellular carcinoma. Liver Int. 2020;40(S1):109–15.

    Article  PubMed  Google Scholar 

  19. Hong K, Georgiades C. Radiofrequency Ablation: Mechanism of Action and Devices. J Vasc Interv Radiol. 2010 Aug 1;21(8, Supplement):S179–86.

    Article  PubMed  Google Scholar 

  20. Erinjeri JP, Clark TWI. Cryoablation: Mechanism of Action and Devices. J Vasc Interv Radiol. 2010 Aug 1;21(8, Supplement):S187–91.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lubner MG, Brace CL, Hinshaw JL, Lee FT. Microwave Tumor Ablation: Mechanism of Action, Clinical Results, and Devices. J Vasc Interv Radiol. 2010 Aug 1;21(8, Supplement):S192–203.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging After Percutaneous Radiofrequency Ablation of Hepatic Tumors: Part 1, Normal Findings. Am J Roentgenol. 2013 Jan 1;200(1):184–93.

    Article  Google Scholar 

  23. MRI assessment of hepatocellular carcinoma after locoregional therapy [Internet]. [cited 2019 Dec 19]. Available from: https://www.readcube.com/library/f4ae90b1-d3ea-46ee-a46b-e45d9fea9705:615eebd9-15fe-4b83-8d37-70045713915e

  24. Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging After Percutaneous Radiofrequency Ablation of Hepatic Tumors: Part 2, Abnormal Findings. Am J Roentgenol. 2013 Jan 1;200(1):194–204.

    Article  Google Scholar 

  25. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin. Am J Roentgenol. 2007 Feb 1;188(2):480–8.

    Article  Google Scholar 

  26. Shyn PB, Mauri G, Alencar RO, Tatli S, Shah SH, Morrison PR, et al. Percutaneous Imaging-Guided Cryoablation of Liver Tumors: Predicting Local Progression on 24-Hour MRI. Am J Roentgenol. 2014 Feb 20;203(2):W181–91.

    Article  Google Scholar 

  27. Lahat E, Eshkenazy R, Zendel A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr. 2014 Oct;3(5):317–23.

    PubMed  PubMed Central  Google Scholar 

  28. Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol. 2016 Apr 1;41(4):767–80.

    Article  Google Scholar 

  29. Complications from percutaneous microwave ablation of liver tumours: a pictorial review [Internet]. [cited 2020 Aug 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636263/

  30. Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, et al. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2016;22(11):1491–500.

    Google Scholar 

  31. Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol. 2018 Jun 28;6(2):189–97.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Chung W-S, Lee K-H, Park M-S, Lee YJ, Kwon J, Baek S-E, et al. Enhancement Patterns of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Drug-Eluting Beads on Arterial Phase CT Images: A Pilot Retrospective Study. Am J Roentgenol. 2012 Aug 1;199(2):349–59.

    Article  Google Scholar 

  33. Chiu RYW, Yap WW, Patel R, Liu D, Klass D, Harris AC. Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging. Can Assoc Radiol J. 2016 May 1;67(2):158–72.

    Article  PubMed  Google Scholar 

  34. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, et al. The Role of Functional MR Imaging in the Assessment of Tumor Response after Chemoembolization in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2006 Mar 1;17(3):505–12.

    Article  PubMed  Google Scholar 

  35. Liu Z, Fan J-M, He C, Li Z-F, Xu Y-S, Li Z, et al. Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis. Cancer Imaging. 2020 Jan 6;20(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Brennan IM, Ahmed M. Imaging Features Following Transarterial Chemoembolization and Radiofrequency Ablation of Hepatocellular Carcinoma. Semin Ultrasound CT MRI. 2013 Aug 1;34(4):336–51.

    Article  Google Scholar 

  37. Chung J, Yu J-S, Chung J-J, Kim JH, Kim KW. Haemodynamic events and localised parenchymal changes following transcatheter arterial chemoembolisation for hepatic malignancy: interpretation of imaging findings. Br J Radiol. 2010 Jan;83(985):71–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nishida K, Lefor AK, Funabiki T. Rupture of Hepatocellular Carcinoma after Transarterial Chemoembolization followed by Massive Gastric Bleeding. Case Rep Hepatol [Internet]. 2018 Jun 4 [cited 2020 May 28];2018. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008880/

  39. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical Aspects of Radioembolization with 90Y Microspheres. Tech Vasc Interv Radiol. 2007 Mar 1;10(1):12–29.

    Article  PubMed  Google Scholar 

  40. Vesselle G, Petit I, Boucebci S, Rocher T, Velasco S, Tasu J-P. Radioembolization with yttrium-90 microspheres work up: Practical approach and literature review. Diagn Interv Imaging. 2015 Jun 1;96(6):547–62.

    Article  CAS  PubMed  Google Scholar 

  41. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13–23.

    Article  PubMed  Google Scholar 

  42. Woerner AJ, Johnson GE. Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma. Hepatoma Res. 2022 Jan 6;8:2.

    Google Scholar 

  43. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006 Aug;29(4):522–9.

    Article  PubMed  Google Scholar 

  44. Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. RadioGraphics. 2019 Mar 1;39(2):578–95.

    Article  PubMed  Google Scholar 

  45. Mora RA, Ali R, Gabr A, Abouchaleh N, Asadi AA, Kallini JR, et al. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdom Radiol. 2018 Jul 1;43(7):1723–38.

    Article  Google Scholar 

  46. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Spear GG, Mulcahy MF, et al. Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49(4):1185–93.

    Article  PubMed  Google Scholar 

  47. Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, et al. Tumor Response after Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Comparison of Diffusion-weighted Functional MR Imaging with Anatomic MR Imaging. J Vasc Interv Radiol. 2008 Aug 1;19(8):1180–6.

    Article  PubMed  Google Scholar 

  48. Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers. Diagnostics. 2015 Dec;5(4):546–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres. J Vasc Interv Radiol. 2008 May 1;19(5):691–7.

    Article  PubMed  Google Scholar 

  50. Braat M, Erpecum K van, Zonnenberg B, Bosch M van den, Lam M. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2017 Feb;29(2):144–52.

    Article  CAS  PubMed  Google Scholar 

  51. Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B, et al. Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1599–604.

    CAS  PubMed  Google Scholar 

  52. Kalogeridi M-A, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, et al. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol. 2015 Jan 27;7(1):101–12.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung T-T, et al. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (Baltimore). 2022 Jan 28;101(4):e28545.

    Article  CAS  Google Scholar 

  54. Lee S, Jung J, Park J, Kim SY, Choi J, Lee D, et al. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer. 2022 Feb 16;22(1):175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zeng Z-C, Seong J, Yoon SM, Cheng JC-H, Lam K-O, Lee A-S, et al. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017 Nov;6(4):264–74.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Mastrocostas K, Jang H-J, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, et al. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol. 2019 May 1;44(5):1795–807.

    Article  Google Scholar 

  57. Haddad MM, Merrell KW, Hallemeier CL, Johnson GB, Mounajjed T, Olivier KR, et al. Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. Abdom Radiol. 2016 Oct 1;41(10):2061–77.

    Article  Google Scholar 

  58. Mendiratta-Lala M, Gu E, Owen D, Cuneo KC, Bazzi L, Lawrence TS, et al. Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 15;102(4):1063–9.

    Article  PubMed  Google Scholar 

  59. Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, et al. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. Int J Radiat Oncol • Biol • Phys. 2019 Jan 1;103(1):169–79.

    Article  PubMed  Google Scholar 

  60. Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, et al. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLOS ONE. 2017 Apr 25;12(4):e0176118.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol. 2019 Feb 1;131:135–44.

    Article  Google Scholar 

  62. Park J, Park JW, Kang MK. Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Yeungnam Univ J Med. 2019 Aug 12;36(3):192–200.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Kellock T, Liang T, Harris A, Schellenberg D, Ma R, Ho S, et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. Br J Radiol [Internet]. 2018 [cited 2020 Aug 10];91(1085). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190776/

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA, 01805, USA

    Mohanned Alnammi, Jeremy Wortman, Jaclyn Therrien & Jalil Afnan

Authors
  1. Mohanned Alnammi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeremy Wortman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaclyn Therrien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jalil Afnan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jalil Afnan.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alnammi, M., Wortman, J., Therrien, J. et al. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol 47, 2299–2313 (2022). https://doi.org/10.1007/s00261-022-03526-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-022-03526-0

Keywords

Search

Navigation